Previous close | 1.6500 |
Open | 1.6500 |
Bid | 1.6100 x 900 |
Ask | 1.6300 x 1000 |
Day's range | 1.6020 - 1.6997 |
52-week range | 1.2500 - 22.7400 |
Volume | |
Avg. volume | 248,361 |
Market cap | 145.87M |
Beta (5Y monthly) | 1.25 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9010 |
Earnings date | 22 Aug 2022 - 26 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.77 |
BEIJING, June 16, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in the virtual Goldman Sachs Healthcare Corporate Day. Genetron’s management team, Sizhen Wang, co-founder and Chief Executive Officer and Evan
BEIJING, June 15, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced College of American Pathologists (CAP) Accreditation for its laboratory in Maryland, U.S. CAP Accreditation is designed to help laboratories maintain the accuracy of test results and
BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the f